← Back to Search

Other

Exoskeletal-Assisted Walking (WALK) for Quadriplegia (EAWSCI Trial)

N/A
Waitlist Available
Led By Ann M Spungen, EdD
Research Sponsored by James J. Peters Veterans Affairs Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up session 12 (1 month)
Awards & highlights

EAWSCI Trial Summary

The primary objective of this study is to achieve successful walking skills using exoskeletal walking devices over the course of 36 sessions in 3 months at specific velocities and distances in people with chronic SCI who are wheelchair dependent for community mobility. The secondary objectives are to determine if this amount of exoskeletal walking is effective in improving bowel function and body composition in the same patient population. The exploratory objectives are to address additional questions concerning the retention or non-retention of the positive changes, the effects of the increased physical activity from this intervention on vagal tone, orthostatic tolerance, lipid profile, total testosterone, estradiol levels, and quality of life (QOL). A Phase III randomized clinical trial (RCT) will be performed using a crossover design and employing an exoskeletal-assisted walking intervention. The experimental arm will be compared to a usual activities (UA) arm, as the control, in 64 persons with chronic SCI (>6 month post injury) who are wheelchair-dependent for outdoor mobility in the community. The WALK arm will consist of supervised exoskeletal-assisted walking training, three sessions per week (4-6 h/week) for 36 sessions for their second 12-week period. The UA arm will consist of identification of usual activities for each participant, encouragement to continue with these activities and attention by study team members throughout the 12-week UA arm. These activities will be recorded in a weekly log. The investigators hypotheses are that 1) this exoskeletal intervention will be successful in training ambulatory skills in this patient population, 2) the exoskeletal intervention will be better than a control group in improving body composition, bowel function, metabolic parameters and quality of life in the same population.

Eligible Conditions
  • Quadriplegia
  • Paraplegia
  • Spinal Cord Injury

EAWSCI Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~session 12 (1 month)
This trial's timeline: 3 weeks for screening, Varies for treatment, and session 12 (1 month) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
10meter Walk Test
6min Walk Test
Gait, Unsteady
+1 more
Secondary outcome measures
Bowel Function
Total body fat mass

EAWSCI Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Exoskeletal-Assisted Walking (WALK)Experimental Treatment1 Intervention
WALK first for 12 weeks (36 sessions)
Group II: Usual Activities (UA)Active Control1 Intervention
Usual activities first for 12 weeks

Find a Location

Who is running the clinical trial?

James J. Peters Veterans Affairs Medical CenterLead Sponsor
57 Previous Clinical Trials
2,836 Total Patients Enrolled
5 Trials studying Quadriplegia
158 Patients Enrolled for Quadriplegia
Ann M Spungen, EdDPrincipal InvestigatorJames J Peters VAMC
6 Previous Clinical Trials
813 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~6 spots leftby Apr 2025